Medtronic MDT financials

Healthcare & Pharma · Statements and segments from its SEC filings, 2013 to 2026.

Medtronic revenue, gross and operating margin, net income, free cash flow, cash and debt by quarter and by fiscal year, and revenue by segment, read from the company's own filings with the US Securities and Exchange Commission. Free to everyone; the Risk & Quality report that scores the company is the paid step.

revenue by segment: Cardiovascular, Neuroscience, Medical Surgical, Diabetes, Other operating segment, misc, Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group
revenue by region: Rest of world, United States, Ireland, Americas, Non-U.S. Developed Markets, EMEA, Emerging Markets, Asia Pacific, Greater China
operating income by segment: Cardiovascular, Neuroscience, Medical Surgical, Other Operating Segments, Including Diabetes, Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, Diabetes, Other operating segment

The numbers

Annual figures

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$29.7B	$30B	$30.6B	$28.9B	$30.1B	$31.7B	$31.2B	$32.4B	$33.5B	$36.4B
Gross profit	$20.4B	$20.9B	$21.4B*	$19.5B*	$19.6B*	$21.5B*	$20.5B*	$21.1B*	$21.9B*	$23.6B*
Operating income	$5.4B	$6.6B	$6.3B	$4.8B	$4.5B	$5.8B	$5.5B	$5.1B	$6B	$6.5B
Net income	$4B	$3.1B	$4.6B	$4.8B	$3.6B	$5B	$3.8B	$3.7B	$4.7B	$4.8B
EPS (diluted)	$2.89	$2.27	$3.41	$3.54	$2.66	$3.73	$2.82	$2.76	$3.61	$3.73
Operating cash flow	$6.9B	$4.7B	$7B	$7.2B	$6.2B	$7.3B	$6B	$6.8B	$7B	$7.3B
Free cash flow	$5.6B*	$3.6B*	$5.9B*	$6B*	$4.9B*	$6B*	$4.6B*	$5.2B*	$5.2B*	$5.4B*
Cash & equivalents	$5B	$3.7B	$4.4B	$4.1B	$3.6B	$3.7B	$1.5B	$1.3B	$2.2B	$1.9B
Total debt	$25.9B	$23.7B	$24.5B	$22B	$26.4B	$20.4B	$24.3B	$23.9B	$25.6B	$26.2B
Gross margin	68.7%	69.8%	70.0%	67.4%	65.2%	68.0%	65.7%	65.3%	65.3%	65.0%
Operating margin	18.1%	22.2%	20.5%	16.6%	14.9%	18.2%	17.6%	15.9%	17.8%	17.8%
Net margin	13.6%	10.4%	15.2%	16.6%	12.0%	15.9%	12.0%	11.4%	13.9%	13.2%

Latest quarters

Line	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	$8.4B	$8.3B	$8.9B*	$8.6B	$9B	$9B	$9.8B*	$9.8B
Gross profit	$5.5B*	$5.5B*	$5.8B*	$5.6B*	$5.9B*	$5.8B*	$6.4B*	$6.3B*
Operating income	$1.6B	$1.6B	$1.4B*	$1.4B	$1.7B	$1.5B	$1.9B*	$1.8B
Net income	$1.3B	$1.3B	$1.1B*	$1B	$1.4B	$1.1B	$1.2B*	$1.5B
EPS (diluted)	$0.99	$1.01	$0.82*	$0.81	$1.07	$0.89	$0.97*	$1.14
Operating cash flow	$958M*	$2.6B*	$2.5B*	$1.1B	$925M*	$2.7B*	$2.6B*	$1.8B
Free cash flow	$554M*	$2.1B*	$2.1B*	$584M*	$457M*	$2.3B*	$2.1B*	$1.3B*
Cash & equivalents	$1.4B	$1.2B	$2.2B	$1.3B	$1.3B	$1.1B	$1.9B	$1.7B
Total debt	$24.6B	$24B	$25.6B	$26.2B	$27.7B	$27.9B	$26.2B	$25.6B
Gross margin	64.9%	66.5%	64.7%	65.0%	65.8%	63.8%	65.4%	65.0%
Operating margin	19.0%	19.9%	16.1%	16.8%	18.8%	16.2%	19.1%	18.1%
Net margin	15.1%	15.6%	11.8%	12.1%	15.3%	12.7%	12.7%	15.1%

Revenue by segment

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cardiovascular	-	-	-	-	$10.8B	$11.4B	$11.6B	$11.8B	$12.5B	$14B
Neuroscience	-	-	-	-	$8.2B	$8.8B	$9B	$9.4B	$9.8B	$10.3B
Medical Surgical	-	-	-	-	$8.7B	$9.1B	$8.4B	$8.4B	$8.4B	$8.8B
Diabetes	$1.9B	$2.1B	$2.4B	$2.4B	$2.4B	$2.3B	$2.3B	$2.5B	$2.8B	$3.1B
Other operating segment, misc	-	-	-	-	-	-	-	$221M	$137M	$135M
Cardiac and Vascular Group	$10.5B	$11.4B	$11.5B	$10.5B	-	-	-	-	-	-
Minimally Invasive Therapies Group	$9.9B	$8.7B	$8.5B	$8.4B	-	-	-	-	-	-
Restorative Therapies Group	$7.4B	$7.7B	$8.2B	$7.7B	-	-	-	-	-	-

Revenue by region

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Rest of world	-	-	-	-	-	-	-	$15.7B	$16.3B	$18.1B
United States	-	$15.9B	$16.2B	$14.9B	$15.5B	$16.1B	$16.4B	$16.6B	$17.2B	$18.1B
Ireland	-	$85M	$91M	$85M	$100M	$101M	$98M	$113M	$116M	$143M
Americas	$17.9B	-	-	-	-	-	-	-	-	-
Non-U.S. Developed Markets	-	$9.6B	$9.6B	$9.3B	$9.8B	$10.1B	$9.4B	-	-	-
EMEA	$6.7B	-	-	-	-	-	-	-	-	-
Emerging Markets	-	$4.5B	$4.7B	$4.7B	$4.8B	$5.4B	$5.4B	-	-	-
Asia Pacific	$3.4B	-	-	-	-	-	-	-	-	-
Greater China	$1.6B	-	-	-	-	-	-	-	-	-

Operating income by segment

Line	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Cardiovascular	-	-	-	$3.9B	$4.5B	$4.4B	$3.1B	$3.3B	$3.7B
Neuroscience	-	-	-	$3.2B	$3.8B	$3.6B	$2.8B	$3B	$3.1B
Medical Surgical	-	-	-	$3B	$3.6B	$2.9B	$2.2B	$2.1B	$2.1B
Other Operating Segments, Including Diabetes	-	-	-	-	-	-	$96M	$214M	$106M
Cardiac and Vascular Group	$4.5B	$4.5B	$3.7B	-	-	-	-	-	-
Minimally Invasive Therapies Group	$3.3B	$3.3B	$3B	-	-	-	-	-	-
Restorative Therapies Group	$3.1B	$3.3B	$2.9B	-	-	-	-	-	-
Diabetes	$634M	$739M	$546M	$598M	$583M	$378M	-	-	-

* derived: a fourth quarter as the year less the three filed quarters, or a remainder as the total less the parts. All other figures are as filed.

About this page

Every figure on this page is read from Medtronic's own SEC filings: the statement lines from the SEC's XBRL company-facts feed, the revenue splits from the segment and revenue notes of each 10-K and 10-Q. Nothing is typed in or estimated. The cache refreshes daily.

Read the Risk & Quality report on Medtronic or see all companies.